Inventiva (IVA.PA) traded down -1.45 % during a 24 hours period ending at 04:37 PM Central Europe on Monday 26th. One Inventiva stock can currently be bought for about EUR 3.39 on popular exchanges. Current supply of Inventiva stocks is 236.3 mn. Inventiva has a current market capitalization of EUR 723 mn and approximately EUR 1.3 mn worth of Inventiva was traded on exchanges in the last 24 hours. Since last month end, Inventiva has traded 10.67 % up. Simple moving average of last 200 days is at EUR 4.21. The highest price of past 52 weeks was recorded at EUR 6.2 on 01/23/2026. 52 weeks low was at EUR 2.57 on 10/14/2026.

Here is how related stocks have performed in the past 24 hours:

  • Voyageurs Du Monde (ALVDM.PA) traded flat 0 % and now trades at EUR 179.5. Voyageurs Du Monde has a market capitalisation of EUR 787.9 mn. Current price/earnings ratio for Voyageurs Du Monde is 16.91.

  • Placoplatre (MLPLC.PA) traded flat 0 % and now trades at EUR 640. Current market capitalisation for Placoplatre is EUR 835.6 mn. Current price/earnings ratio for Placoplatre is 13.1.

  • Mersen (MRN.PA) traded down -1.35 % and now trades at EUR 36.14. Mersen has a market capitalisation of EUR 850.8 mn. Mersen has a current price to earnings ratio of 56.26.

  • Lectra (LSS.PA) traded up 1.81 % and now trades at EUR 22.7. Lectra has a market capitalisation of EUR 839.3 mn. Current price/earnings ratio for Lectra is 36.79.

  • Altamir (LTA.PA) traded flat 0 % and now trades at EUR 22.4. Current market capitalisation for Altamir is EUR 813.4 mn. Altamir has a current price to earnings ratio of 53.96.

About Inventiva

Inventiva SACA is a clinical stage biopharmaceutical company based in Daix, France. The company’s main focus is developing drugs for the treatment of fibrotic diseases, cancers, and orphan diseases. Its lead product candidate, Lanifibranor, is currently in a Phase IIb clinical trial to treat nonalcoholic steatohepatitis and systemic sclerosis. Additionally, Inventiva is developing Odiparcil, which is in a Phase IIa clinical trial for the treatment of mucopolysaccharidosis I, II, and VI diseases; YAP-TEAD, in the preclinical stage for the treatment of malignant mesothelioma and lung cancer; NSD2 for the treatment of multiple myeloma; and EPICURE for immuno-oncology treatment. The company has partnership collaborations with AbbVie, Boehringer Ingelheim, and Institut Curie. You can find more information about Inventiva SACA on their website, www.inventivapharma.com , and they are listed on the NYSE Euronext Paris stock exchange.